Global Novel Oral Anticoagulants Drugs Market Growth (Status and Outlook) 2025-2031

According to this study, the global Novel Oral Anticoagulants Drugs market size will reach US$ 50240 million by 2031.

Anticoagulant drugs (also known as blood thinners) are chemical substances that prevent or reduce coagulation of blood and prolong the blood clotting time.

The antithrombotic treatment market is driven by the increasing prevalence of cardiovascular diseases and the rising aging population, which are significant risk factors for thrombotic disorders. Antithrombotic therapies, including antiplatelet and anticoagulant drugs, play a crucial role in preventing and treating thrombotic events, such as heart attacks and strokes. The growing adoption of these treatments for various thrombotic indications, along with advancements in drug development and personalized medicine, further propel market growth. However, challenges include balancing the risk of bleeding complications with the benefits of preventing thrombotic events, ensuring optimal dosing and adherence to treatment regimens, and addressing the cost burden of long-term therapy. Overcoming these challenges through continuous research, improved patient education, and collaboration between healthcare providers and pharmaceutical companies will be crucial for the sustained growth of the antithrombotic treatment market.

LPI (LP Information)' newest research report, the “Novel Oral Anticoagulants Drugs Industry Forecast” looks at past sales and reviews total world Novel Oral Anticoagulants Drugs sales in 2024, providing a comprehensive analysis by region and market sector of projected Novel Oral Anticoagulants Drugs sales for 2025 through 2031. With Novel Oral Anticoagulants Drugs sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Novel Oral Anticoagulants Drugs industry.

This Insight Report provides a comprehensive analysis of the global Novel Oral Anticoagulants Drugs landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Novel Oral Anticoagulants Drugs portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Novel Oral Anticoagulants Drugs market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Novel Oral Anticoagulants Drugs and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Novel Oral Anticoagulants Drugs.

This report presents a comprehensive overview, market shares, and growth opportunities of Novel Oral Anticoagulants Drugs market by product type, application, key players and key regions and countries.

Segmentation by Type:
Direct Thrombin Inhibitor
Factor Xa Inhibitors

Segmentation by Application:
Hospital
Drugs Stores
Other

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Bristol-Myers Squibb
Bayer
Pfizer
Johnson & Johnson
Boehringer Ingelheim
Daiichi Sankyo

Please note: The report will take approximately 2 business days to prepare and deliver. Show more